within Pharmacolibrary.Drugs.ATC.C;

model C04AE01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.05,
    Cl             = 0.013333333333333334,
    adminDuration  = 600,
    adminMass      = 3 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.016,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C04AE01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Ergoloid mesylates is a mixture of dihydrogenated ergot alkaloids (dihydroergocristine, dihydroergocornine, and dihydroergocryptine) used primarily for cognitive impairment and symptoms of dementia in elderly patients, particularly in the past. It was once approved for the management of dementia and age-related cognitive decline but its clinical use has been largely discontinued or restricted due to limited evidence of efficacy.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adults after oral administration; no primary literature with detailed compartment model pharmacokinetic parameters could be found.</p><h4>References</h4><ol><li><p>Lu, WJ, et al., &amp; Lai, ML (2006). The effects of ergoloid mesylates and ginkgo biloba on the pharmacokinetics of ticlopidine. <i>Journal of clinical pharmacology</i> 46(6) 628–634. DOI:<a href=&quot;https://doi.org/10.1177/0091270006287024&quot;>10.1177/0091270006287024</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16707409/&quot;>https://pubmed.ncbi.nlm.nih.gov/16707409</a></p></li><li><p>Schran, HF, et al., &amp; Lehr, R (1988). Pharmacokinetics and bioavailability of ergoloid mesylates. <i>Biopharmaceutics &amp; drug disposition</i> 9(4) 349–361. DOI:<a href=&quot;https://doi.org/10.1002/bod.2510090404&quot;>10.1002/bod.2510090404</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3207855/&quot;>https://pubmed.ncbi.nlm.nih.gov/3207855</a></p></li><li><p>Schran, HF (1985). Bioavailability of ergoloid mesylates liquid capsule. <i>Clinical therapeutics</i> 8(1) 71–75. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3833371/&quot;>https://pubmed.ncbi.nlm.nih.gov/3833371</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C04AE01;
